ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
NCT00046514
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Metastases, Neoplasm
Interventions
DRUG:
ABI-007
Sponsor
Celgene Corporation